BCRX

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

Peers: VRTX REGN IONS ALNY SRPT PTCT BMRN CRSP BLUE RARE

| Held by: VTI XBI IWM VB VXF IWO IBB VBK PBE SCHA

Index	RUT	P/E	-	EPS (ttm)	-0.05	Insider Own	7.39%	Shs Outstand	210.52M	Perf Week	5.71%
Market Cap	1.60B	Forward P/E	42.79	EPS next Y	0.18	Insider Trans	-1.53%	Shs Float	194.98M	Perf Month	5.86%
Enterprise Value	2.07B	PEG	-	EPS next Q	0.03	Inst Own	95.21%	Short Float	18.70%	Perf Quarter	-7.33%
Income	-8.78M	P/S	2.66	EPS this Y	128.94%	Inst Trans	-5.48%	Short Ratio	7.47	Perf Half Y	-31.25%
Sales	599.82M	P/B	-	EPS next Y	42.53%	ROA	-1.87%	Short Interest	36.46M	Perf YTD	0.93%
Book/sh	-1.84	P/C	7.49	EPS next 5Y	-	ROE	-	52W High	11.31 -32.89%	Perf Year	5.56%
Cash/sh	1.01	P/FCF	33.54	EPS past 3/5Y	25.20% 14.52%	ROIC	-3.43%	52W Low	6.00 26.50%	Perf 3Y	-43.19%
Dividend Est.	-	EV/EBITDA	26.71	Sales past 3/5Y	42.07% 55.97%	Gross Margin	97.17%	Volatility	5.46% 4.13%	Perf 5Y	48.53%
Dividend TTM	-	EV/Sales	3.45	EPS Y/Y TTM	92.85%	Oper. Margin	12.69%	ATR (14)	0.31	Perf 10Y	-26.31%
Dividend Ex-Date	-	Quick Ratio	1.84	Sales Y/Y TTM	45.38%	Profit Margin	-1.46%	RSI (14)	59.48	Recom	1.20
Dividend Gr. 3/5Y	- -	Current Ratio	1.87	EPS Q/Q	186.58%	SMA20	6.04%	Beta	0.80	Target Price	20.40
Payout	-	Debt/Eq	-	Sales Q/Q	36.14%	SMA50	6.38%	Rel Volume	0.66	Prev Close	7.83
Employees	580	LT Debt/Eq	-	Earnings	Nov 03 BMO	SMA200	-8.53%	Avg Volume	4.88M	Price	7.59
IPO	Mar 04, 1994	Option/Short	Yes / Yes	EPS/Sales Surpr.	50.75% -2.20%	Trades		Volume	3,199,156	Change	-3.07%

Date	Action	Analyst	Rating Change	Price Target Change
Oct-15-25	Resumed	TD Cowen	Buy	$30
Oct-01-25	Downgrade	Evercore ISI	Outperform → In-line	$8
Apr-29-25	Initiated	Cantor Fitzgerald	Overweight	$20
Feb-25-25	Initiated	Wedbush	Outperform	$15
Nov-20-23	Resumed	JP Morgan	Overweight	$10
Sep-18-23	Upgrade	RBC Capital Mkts	Sector Perform → Outperform	$9 → $10
Aug-04-23	Upgrade	Jefferies	Hold → Buy	$11
Jul-13-23	Upgrade	BofA Securities	Neutral → Buy	$10
Feb-22-23	Upgrade	Needham	Hold → Buy	$14
Nov-02-22	Upgrade	Evercore ISI	In-line → Outperform	$14 → $16
Aug-05-22	Downgrade	Oppenheimer	Outperform → Perform
Aug-05-22	Downgrade	Evercore ISI	Outperform → In-line	$14
Apr-18-22	Downgrade	Barclays	Overweight → Equal Weight	$22 → $13
Apr-11-22	Downgrade	BofA Securities	Buy → Neutral	$21 → $14
Dec-10-21	Initiated	Oppenheimer	Outperform	$16
Aug-06-21	Downgrade	Jefferies	Buy → Hold
Aug-03-21	Initiated	Cantor Fitzgerald	Overweight	$21
Mar-01-21	Initiated	Cowen	Outperform	$16
Sep-29-20	Resumed	JP Morgan	Overweight	$7
Jun-17-20	Initiated	BTIG Research	Neutral

Show Previous Ratings

Dec-04-25 01:09PM	Pharvaris Stock Gains on HAE Drug Meeting Late-Stage Study Goals (Zacks)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Dec-03-25 07:00AM	BioCryst Receives Early Termination of HSR Waiting Period for Astria Acquisition (GlobeNewswire) +9.64%
Nov-30-25 12:26AM	BioCryst Data Highlights Severe Psychosocial Burden of HAE on Pediatric Patients, Caregivers (Insider Monkey)
Nov-06-25 08:00AM	BioCryst Presents New Data at ACAAI Highlighting Burden of HAE on Pediatric Patients and Caregivers and Sustained Reduction of Attacks in Children Treated with One Year of ORLADEYO (berotralstat) (GlobeNewswire)
07:01AM	Loading…
Nov-05-25 07:01AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire) +6.07%
07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Nov-03-25 04:01PM	BioCryst Pharmaceuticals Inc (BCRX) Q3 2025 Earnings Call Highlights: Strong Orladeo Growth and ... (GuruFocus.com) -6.28%
07:12AM	BioCryst: Q3 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Third Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Oct-31-25 05:42PM	Astria, Viridian Therapeutics, and More Stocks See Action From Activist Investors (Barrons.com)
Oct-30-25 05:40PM	Ardelyx (ARDX) Reports Break-Even Earnings for Q3 (Zacks)
Oct-28-25 10:00AM	Madrigal (MDGL) Expected to Beat Earnings Estimates: Should You Buy? (Zacks)
Oct-27-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Earnings Expected to Grow: Should You Buy? (Zacks)
Oct-23-25 07:00AM	BioCryst to Present New Pediatric HAE Data at the American College of Allergy, Asthma & Immunology 2025 Annual Scientific Meeting (GlobeNewswire)
07:00AM	Loading…
Oct-20-25 07:00AM	BioCryst to Report Third Quarter 2025 Financial Results on November 3 (GlobeNewswire)
Oct-16-25 07:56AM	BioCryst (BCRX) Soars 6.1%: Is Further Upside Left in the Stock? (Zacks)
Oct-15-25 10:05AM	Astria Therapeutics Stock Rallies 37% on $700M Buyout Offer From BCRX (Zacks) +6.07%
09:17AM	Teladoc Health Expands Clarity Platform With Workplace Safety Tool (Zacks)
05:16AM	BioCryst to buy Astria Therapeutics for $700m in enterprise value (Pharmaceutical Technology)
Oct-14-25 08:59AM	Is the Options Market Predicting a Spike in BioCryst Pharmaceuticals Stock? (Zacks) -8.81%
07:32AM	BioCryst goes all in on rare swelling disease with Astria deal (BioPharma Dive)
07:00AM	BioCryst to Acquire Astria Therapeutics, Strengthening Presence in HAE, Transforming Growth Profile (Business Wire)
Oct-07-25 09:35AM	Down 14.3% in 4 Weeks, Here's Why BioCryst (BCRX) Looks Ripe for a Turnaround (Zacks)
Oct-04-25 04:54PM	BioCryst Sells European ORLADEYO Business for $250M Upfront to Focus on US Market (Insider Monkey)
Oct-03-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Oct-01-25 07:00AM	BioCryst Completes Sale of European ORLADEYO (berotralstat) Business (GlobeNewswire)
Sep-11-25 08:31AM	BofA lists 13 SMID cap stocks that could rebound (Investing.com)
Sep-03-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Sep-02-25 04:04AM	BioCryst Pharmaceuticals, Inc. (BCRX) Q2 Revenue Soars 49%, Hits Record $163.4 Million on ORLADEYO Surge (Insider Monkey)
07:00AM	Loading…
Aug-21-25 07:00AM	BioCryst to Present at Upcoming Investor Conference (GlobeNewswire)
Aug-12-25 05:41PM	Are Options Traders Betting on a Big Move in BCRX Stock? (Zacks)
Aug-11-25 07:00AM	BioCryst Announces Departure of Dr. Helen Thackray (GlobeNewswire)
Aug-06-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Aug-05-25 03:00AM	BioCryst Pharmaceuticals Inc (BCRX) Q2 2025 Earnings Call Highlights: Record ORLADEYO Revenue ... (GuruFocus.com)
Aug-04-25 08:15AM	BioCryst Pharmaceuticals (BCRX) Surpasses Q2 Earnings and Revenue Estimates (Zacks) +9.81%
07:12AM	BioCryst: Q2 Earnings Snapshot (Associated Press Finance)
07:00AM	BioCryst Reports Second Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
Jul-31-25 01:12PM	BioCryst Pharmaceuticals Before Q2 Earnings: How to Play the Stock (Zacks)
07:00AM	BioCryst Announces Charlie Gayer to Succeed Jon Stonehouse as Chief Executive Officer Upon his Retirement in December (GlobeNewswire)
Jul-29-25 10:00AM	Analysts Estimate Esperion Therapeutics (ESPR) to Report a Decline in Earnings: What to Look Out for (Zacks)
Jul-28-25 10:00AM	BioCryst Pharmaceuticals (BCRX) Reports Next Week: Wall Street Expects Earnings Growth (Zacks)
Jul-21-25 07:00AM	BioCryst to Report Second Quarter 2025 Financial Results on August 4 (GlobeNewswire)
Jul-15-25 10:00AM	AscellaHealths Patient-Focused Approach is Best-in-Class Model for Distribution of Rare Disease Therapies (GlobeNewswire)
Jul-11-25 11:27AM	RBC Capital Maintained a Buy on BioCryst Pharmaceutical (BCRX), Sets a PT of $13 (Insider Monkey)
Jul-09-25 07:00AM	BioCryst to Highlight Patient-focused Research at the 2025 US HAEA National Summit (GlobeNewswire)
Jul-07-25 09:40AM	Is BioCryst Pharmaceuticals (BCRX) Outperforming Other Medical Stocks This Year? (Zacks)
07:00AM	BioCryst Appoints Babar Ghias Chief Financial Officer and Head of Corporate Development (GlobeNewswire)
Jul-06-25 04:00AM	BioCryst Pharmaceuticals Sells European ORLADEYO Business for Up to $264M (Insider Monkey)
Jul-03-25 01:51PM	Ensign Group Boosts U.S. Presence With Idaho and Texas Facility Buyouts (Zacks)
07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-30-25 01:05PM	Select Medical Expands Presence in Tennessee With Ballad Health Deal (Zacks)
Jun-27-25 07:00AM	BioCryst Announces Sale of European ORLADEYO (berotralstat) Business to Neopharmed Gentili for up to $264 Million (GlobeNewswire)
Jun-26-25 04:32AM	Zacks.com featured highlights ASR, INSW, BCRX, ASC and RRGB (Zacks)
Jun-25-25 12:00PM	BioCryst (BCRX) Upgraded to Strong Buy: What Does It Mean for the Stock? (Zacks)
07:51AM	5 Must-Buy Efficient Stocks to Buy for Solid Gains Amid Volatility (Zacks)
06:16AM	New Strong Buy Stocks for June 25th (Zacks)
Jun-18-25 09:40AM	Is GEN DIGITAL INC (GEN) Stock Outpacing Its Business Services Peers This Year? (Zacks)
09:40AM	Is Atmos Energy (ATO) Outperforming Other Utilities Stocks This Year? (Zacks)
09:40AM	Is Apollo Commercial Real Estate Finance (ARI) Stock Outpacing Its Finance Peers This Year? (Zacks)
09:40AM	Has Heico (HEI) Outpaced Other Aerospace Stocks This Year? (Zacks)
09:40AM	Has ASML Holding (ASML) Outpaced Other Computer and Technology Stocks This Year? (Zacks)
09:40AM	Has Aris Mining Corporation (ARMN) Outpaced Other Basic Materials Stocks This Year? (Zacks)
09:40AM	Are Medical Stocks Lagging Acurx Pharmaceuticals (ACXP) This Year? (Zacks)
09:40AM	Are Industrial Products Stocks Lagging Andritz (ADRZY) This Year? (Zacks)
09:40AM	Are Construction Stocks Lagging AECOM (ACM) This Year? (Zacks)
Jun-16-25 07:00AM	BioCryst Presents New Data on the Long-term Efficacy and Safety of ORLADEYO (berotralstat) Across all Ages at EAACI (GlobeNewswire)
Jun-13-25 07:00AM	ORLADEYO (berotralstat) Approved in Colombia (GlobeNewswire)
02:32AM	United Therapeutics (UTHR) Soars 3.5%: Is Further Upside Left in the Stock? (Zacks)
Jun-06-25 07:00AM	BioCryst Achieves Reimbursement for ORLADEYO Across all Major European Countries (GlobeNewswire)
Jun-04-25 12:00PM	BioCryst Pharmaceuticals (BCRX) is a Great Momentum Stock: Should You Buy? (Zacks)
10:00AM	Best Momentum Stock to Buy for June 4th (Zacks)
05:52AM	New Strong Buy Stocks for June 4th (Zacks)
Jun-03-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
Jun-02-25 07:00AM	BioCryst to Present New Data at 2025 Meeting of the European Academy of Allergy and Clinical Immunology (GlobeNewswire)
May-30-25 07:00AM	BioCryst Highlights Real-world Data Showing ORLADEYO (berotralstat) Consistently Reduces HAE Attacks Across All Ages (GlobeNewswire)
May-28-25 09:40AM	Is Bayer (BAYRY) Outperforming Other Medical Stocks This Year? (Zacks)
May-27-25 07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
May-26-25 09:55AM	Wall Street Analysts Believe BioCryst (BCRX) Could Rally 55.81%: Here's is How to Trade (Zacks)
May-16-25 07:00AM	BioCryst Presents New Real-world Evidence Showing Significant and Sustained Reductions in HAE Attack Rates in Adolescents and People with Severe HAE Following Initiation of ORLADEYO (berotralstat) (GlobeNewswire)
May-15-25 09:40AM	FDA awards BioCrysts Orladeyo NDA for paediatric HAE (Pharmaceutical Technology)
May-14-25 07:00AM	BioCryst Announces FDA Acceptance of NDA for ORLADEYO (berotralstat) Oral Granules in Patients with Hereditary Angioedema Aged 2 to 11 Years (GlobeNewswire)
May-09-25 10:00AM	Best Momentum Stocks to Buy for May 9th (Zacks)
07:08AM	New Strong Buy Stocks for May 9th (Zacks)
May-08-25 12:20PM	Why BioCryst (BCRX) Might be Well Poised for a Surge (Zacks)
12:00PM	What Makes BioCryst Pharmaceuticals (BCRX) a Strong Momentum Stock: Buy Now? (Zacks)
09:55AM	Does BioCryst (BCRX) Have the Potential to Rally 61.21% as Wall Street Analysts Expect? (Zacks)
May-06-25 04:50AM	Why BioCryst Pharmaceuticals, Inc. (BCRX) Soared on Monday (Insider Monkey) -6.89%
03:02AM	BioCryst Pharmaceuticals Inc (BCRX) Q1 2025 Earnings Call Highlights: Strong ORLADEYO Sales ... (GuruFocus.com)
12:56AM	Q1 2025 BioCryst Pharmaceuticals Inc Earnings Call (Thomson Reuters StreetEvents)
May-05-25 02:05PM	BioCryst: Strong Opportunity For A Double With A Proven Therapy (Seeking Alpha) +23.52%
12:54PM	BioCryst Pharmaceuticals, Inc. (BCRX) Q1 2025 Earnings Call Transcript (Seeking Alpha)
08:20AM	BioCryst Pharmaceuticals (BCRX) Reports Break-Even Earnings for Q1 (Zacks)
07:00AM	BioCryst Reports First Quarter 2025 Financial Results and Provides Business Update (GlobeNewswire)
May-02-25 07:00AM	BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) (GlobeNewswire)
May-01-25 07:00AM	BioCryst Appoints Steve Frank to Board of Directors (GlobeNewswire)
Apr-30-25 10:01AM	Inotiv, Inc. (NOTV) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
07:00AM	BioCryst to Present at Upcoming Investor Conferences (GlobeNewswire)
Apr-28-25 10:00AM	BioCryst Pharmaceuticals (BCRX) May Report Negative Earnings: Know the Trend Ahead of Next Week's Release (Zacks)
Apr-21-25 07:00AM	BioCryst to Report First Quarter 2025 Financial Results on May 5 (GlobeNewswire)

BioCryst Pharmaceuticals, Inc. is a biotechnology company. It engages in the provision of structure-guided drug design with the goal of developing oral small-molecule and protein therapeutics to target difficult-to-treat rare diseases. The company was founded by William M. Spencer III, Charles E. Bugg, and John A. Montgomery in 1986 and is headquartered in Durham, NC.

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Barnes Alane P	Chief Legal Officer	Dec 01 '25	Option Exercise	3.22	91,004	293,033	507,156	Dec 03 06:40 PM
Barnes Alane P	Chief Legal Officer	Dec 01 '25	Sale	7.10	91,004	646,511	416,152	Dec 03 06:40 PM
Barnes Alane P	Chief Legal Officer	Dec 02 '25	Sale	7.21	50,906	367,216	365,246	Dec 03 06:40 PM
Barnes Alane P	Chief Legal Officer	Dec 03 '25	Sale	7.65	19,770	151,240	345,476	Dec 03 06:40 PM
Barnes Alane P	Officer	Dec 03 '25	Proposed Sale	7.65	19,770	151,240		Dec 03 02:01 PM
Barnes Alane P	Officer	Dec 02 '25	Proposed Sale	7.21	50,906	367,216		Dec 02 02:09 PM
Barnes Alane P	Officer	Dec 01 '25	Proposed Sale	7.08	91,004	644,308		Dec 01 12:51 PM
Helen M Thackray	Officer	Nov 25 '25	Proposed Sale	6.80	48,229	327,957		Nov 25 04:31 PM
Helen Thackray	Officer	Nov 21 '25	Proposed Sale	7.11	43,275	307,685		Nov 21 04:29 PM
SANDERS MACHELLE	Director	Nov 13 '25	Sale	7.14	9,600	68,544	30,642	Nov 17 04:07 PM
SANDERS MACHELLE	Officer	Nov 13 '25	Proposed Sale	7.14	9,600	68,544		Nov 13 10:21 AM
HEGGIE THERESA	Director	Aug 13 '25	Option Exercise	4.34	70,000	303,700	135,352	Aug 15 08:24 AM
HEGGIE THERESA	Director	Aug 13 '25	Sale	8.51	70,000	595,868	65,352	Aug 15 08:24 AM
HEGGIE THERESA	Director	Aug 13 '25	Proposed Sale	8.51	70,000	595,871		Aug 13 12:17 PM
Hutson Nancy J	Director	Dec 13 '24	Sale	7.54	7,000	52,780	86,638	Dec 16 04:35 PM
Hutson Nancy J	Director	Dec 13 '24	Proposed Sale	7.51	7,000	52,584		Dec 13 04:23 PM

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

Biocryst Pharmaceuticals Inc

Upgrade your FINVIZ experience